Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $7.8 million.

  • Haemonetics' Share-based Compensation fell 505.23% to $7.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $31.6 million, marking a year-over-year increase of 504.0%. This contributed to the annual value of $29.6 million for FY2025, which is 460.26% up from last year.
  • Per Haemonetics' latest filing, its Share-based Compensation stood at $7.8 million for Q4 2025, which was down 505.23% from $7.6 million recorded in Q3 2025.
  • Haemonetics' 5-year Share-based Compensation high stood at $9.3 million for Q2 2025, and its period low was $5.1 million during Q2 2022.
  • Its 5-year average for Share-based Compensation is $7.0 million, with a median of $7.0 million in 2023.
  • Per our database at Business Quant, Haemonetics' Share-based Compensation tumbled by 2831.22% in 2022 and then surged by 3847.36% in 2023.
  • Over the past 5 years, Haemonetics' Share-based Compensation (Quarter) stood at $6.0 million in 2021, then rose by 25.29% to $7.5 million in 2022, then decreased by 3.66% to $7.2 million in 2023, then increased by 13.81% to $8.2 million in 2024, then fell by 5.05% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q4 2025, $7.6 million for Q3 2025, and $9.3 million during Q2 2025.